Opus Genetics, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging -10.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.15 | $-0.14 | +6.7% | Beat | |
| Q1 FY26 | not reported | $-0.75 | not reported | not reported | |
| Q4 FY25 | $-0.11 | $-0.14 | -27.3% | Miss |
Back to IRD overview · IRD holders · IRD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.